Centrexion Therapeutics Corp (CNTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Centrexion Therapeutics Corp (CNTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10956
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Centrexion Therapeutics Corp (Centrexion Therapeutics), formerly Centrexion Corp is a developer of clinical pipelines of novel and non opioid chronic pain therapy products. The company offers products such as CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, CNTX-6016 and Intrathecalplatform. Its synthetic trans capsaicin ultra-pure injection develops a proprietary injectable therapy designed to provide fast acting, long lasting and targeted pain relief. Centrexion Therapeutics products are used to treat morton’s neuroma and knee osteoarthritis. The company’s research and clinical trial develops novel pain therapeutics for various conditions. Centrexion Therapeutics is headquartered in Boston, Massachusetts, the US.

Centrexion Therapeutics Corp (CNTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Centrexion Therapeutics Raises USD67 Million in Series D Financing 11
Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 13
Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 14
Centrexion Therapeutics Raises USD11.1 Million in Financing Round 15
Centrexion Therapeutics Raises USD7 Million in Venture Financing 16
Centrexion Raises USD14.7 Million in Venture Financing 17
Centrexion Therapeutics Raises USD8.8 Million in Financing Round 18
Licensing Agreements 19
Centrexion Therapeutics Amends Licensing Agreement with Boehringer Ingelheim 19
Equity Offering 20
Centrexion Therapeutics to Raise up to USD80 Million in IPO of Shares 20
Debt Offering 21
Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21
Centrexion Therapeutics Corp – Key Competitors 22
Centrexion Therapeutics Corp – Key Employees 23
Centrexion Therapeutics Corp – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Sep 24, 2018: Centrexion Therapeutics names Andrew Partridge as executive vice president, chief commercial officer 25
Aug 15, 2018: Centrexion Therapeutics names Dan Mendelson as Board Director 26
Jul 30, 2018: Centrexion Therapeutics names Nick Harvey as chief financial officer 27
Jun 26, 2018: Centrexion Therapeutics Names Joseph R. Swedish As Board Director 28
Jun 26, 2017: Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors 29
Product News 30
08/29/2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017 30
06/07/2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology 31
05/10/2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting 32
Product Approvals 33
Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain 33
Clinical Trials 34
Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018 34
Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017 35
Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit 36
Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting 37
Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain 38
May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress 40
Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA 41
Mar 16, 2017: Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Centrexion Therapeutics Raises USD67 Million in Series D Financing 11
Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 13
Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 14
Centrexion Therapeutics Raises USD11.1 Million in Financing Round 15
Centrexion Therapeutics Raises USD7 Million in Venture Financing 16
Centrexion Raises USD14.7 Million in Venture Financing 17
Centrexion Therapeutics Raises USD8.8 Million in Financing Round 18
Centrexion Therapeutics Amends Licensing Agreement with Boehringer Ingelheim 19
Centrexion Therapeutics to Raise up to USD80 Million in IPO of Shares 20
Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21
Centrexion Therapeutics Corp, Key Competitors 22
Centrexion Therapeutics Corp, Key Employees 23

List of Figures
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Centrexion Therapeutics Corp (CNTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Transnet SOC Ltd:企業の戦略的SWOT分析
    Transnet SOC Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Covanta Holding Corp (CVA):企業の財務・戦略的SWOT分析
    Covanta Holding Corp (CVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Red Electrica Corporacion SA (REE):電力:M&Aディール及び事業提携情報
    Summary Red Electrica Corporacion SA (REC), together with its subsidiaries undertakes electricity transmission and system operation and management of the transmission network for the Spanish electricity system. The company carries out the regulated activities through its principal subsidiary, Red El …
  • Emlin Cosmetics :企業の戦略・SWOT・財務情報
    Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report Summary Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GS Engineering & Construction Corp (006360):企業の財務・戦略的SWOT分析
    GS Engineering & Construction Corp (006360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • MilliporeSigma:医療機器:M&Aディール及び事業提携情報
    Summary MilliporeSigma, formerly Sigma-Aldrich Corp, a subsidiary of Merck KGaA is a life sciences and technology company which offers biochemical and organic chemical products, kits and services. Its products and services find application in scientific research including genomic and proteomic resea …
  • Aurigene Discovery Technologies Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Aurigene Discovery Technologies Ltd (Aurigene), a subsidiary of Dr. Reddy's Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns inte …
  • 1-800-FLOWERS.COM Inc (FLWS):企業の財務・戦略的SWOT分析
    1-800-FLOWERS.COM Inc (FLWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Chubu Electric Power Company, Incorporated:企業の戦略・SWOT・財務情報
    Chubu Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Chubu Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • ObsEva SA (OBSV):製薬・医療:M&Aディール及び事業提携情報
    Summary ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company's product portfolio comprises pipeline products which is being developed to control preterm labor by reducing inflammation, decre …
  • Gulfport Energy Corp (GPOR):企業の財務・戦略的SWOT分析
    Gulfport Energy Corp (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • GP Batteries International Ltd:企業の戦略的SWOT分析
    GP Batteries International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Efore Oyj (EFO1V):企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Indiana Municipal Power Agency:電力:M&Aディール及び事業提携情報
    Summary Indiana Municipal Power Agency (IMPA) is a not-for-profit wholesale power provider supplying power to cities and communities across Indiana and Ohio. The agency was formed by its member utilities which enable them to share power resources and provide electricity economically to their custome …
  • Spotlight Innovation Inc (STLT):企業の財務・戦略的SWOT分析
    Summary Spotlight Innovation Inc (Spotlight Innovation), formerly American Exploration Corp is a developer of proprietary technologies designed to treat rare, emerging and neglected diseases. The company’s product pipeline includes drug candidates for the treatment of cancer derived from specialized …
  • Australian Gas Networks Ltd:電力:M&Aディール及び事業提携情報
    Summary Australian Gas Networks Ltd (Australian Gas Networks), formerly Envestra Ltd is an oil and gas company that distributes and transports natural gas. The company's services include managing the haulage of gas through each network, operation and maintenance of gas network, design an constructio …
  • LG Electronics, Inc.:戦略・SWOT・企業財務分析
    LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Prismic Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Prismic Pharmaceuticals Inc (Prismic Pharmaceuticals) is a pharmaceutical company that provides research and development of prescription drugs which has unique safety profiles. The company develops drugs for inflammatory diseases and oxidative stress disorders. It pipeline products are used …
  • Swiss International Air Lines Ltd.:企業の戦略・SWOT・財務情報
    Swiss International Air Lines Ltd. - Strategy, SWOT and Corporate Finance Report Summary Swiss International Air Lines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • CorVel Corporation:企業の戦略・SWOT・財務情報
    CorVel Corporation - Strategy, SWOT and Corporate Finance Report Summary CorVel Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆